文献资料 > 类癌综合征
Carcinoid syndrome from small bowel endocrine carcinoma in the absence of hepatic metastasis2015.07.07
没有肝转移的小肠内分泌癌患者出现类癌综合征
一个80岁男性患者出现腹痛、阵发性出汗、腹泻和呕吐症状,CT扫描显示为小肠内分泌癌(或类癌的肿瘤),但是该患者没有肝脏疾病。手术将病变部位整块切除,在肿瘤的切除手术中,病人的血压波动很大,出现严重的低血压。类癌综合征通常在胃肠道肿瘤肝转移时发生,引起皮肤潮...
Carcinoid syndrome and perioperative anesthetic considerations2015.07.07
类癌综合征及围手术期麻醉的注意事项
类癌是一种罕见的、生长缓慢的肿瘤,这些肿瘤能够分泌多种生物活性物质,这会导致类癌综合征患者的管理存在潜在的挑战。在过去的二十年中,外科手术和医疗的治疗方案得到扩展,从而改善了治疗的结果。本文将介绍类癌综合征的病理生理学、临床症状、体征、诊断、治疗方案...
Early Diffuse Coronary Artery Spasm After Heart Valve Surgery in the Carcinoid Syndrome2015.07.07
早期弥漫性冠状动脉痉挛后进行心脏瓣膜手术的类癌综合征
类癌性心脏病的文献中描述了冠状动脉痉挛,但是能及时拍摄围手术期的冠状动脉痉挛的信息却很少。方法:我们描述了一位类癌性心脏病患者发生严重的冠状动脉痉挛情况下,立即进行三尖瓣手术,导致了患者严重的心脏衰竭。结果:经冠状动脉造影确诊,并在冠状动脉内注射三硝...
In patients with carcinoid syndrome undergoing valve replacement, will a biological valve have acceptable durability?2015.07.07
类癌综合征患者接受心脏瓣膜置换手术,该生物瓣膜能否具有较好的耐久性呢?
根据外科手术的框架协议,我们讲述了一个最好的证据话题。本文提出的问题是:“类癌综合征患者接受心脏瓣膜置换手术,该生物瓣膜能否具有较好的耐久性呢?”搜索发现130多篇论文的使用报告,其中17篇代表了临床问题的最佳回答。从作者、期刊、日期、出版国、病例组研究、...
A case of carcinoid pericardial metastases and massive effusion2015.07.07
A 74-year-old man with arterial hypertension, diabetes, persistent atrial fibrillation, disseminated carcinoid tumour and chronic renal failure was admitted because of hypotension and dyspnoea. His blood pressure was 80/50 mm Hg, and heart rate was i...
A thymic carcinoid tumour causing Zollinger-Ellison and Cushing’s syndromes due to ectopic ACTH and gastrin secretion2015.07.07
Cushings’s syndrome due to ectopic adrenocorticotrophin (ACTH) secretion was first described nearly a century ago by Hurst Brown.1 Bronchial carcinomas, usually bronchial carcinoids, were the first to be described and continue to be the leading caus...
Carcinoid crisis 24 hours after bland embolization: A case report2015.07.07
Within 24 h of bland embolization of carcinoid liver metastasis, patient developed flushing and severe hypotension consistent with carcinoid crisis. Octreotide pre- and postprocedure remains the mainstay for prevention and treatment of carcinoid cris...
Carcinoid syndrome12015.07.07
AbstractAs clinical awareness increases, carcinoidis becoming increasingly identified, often at an earlier stage in the course ofthe disease. However, many patients remain undiagnosed until well into the latestages of the illness, at the time when th...
Carcinoid syndrome2015.07.07
Carcinoid syndrome consists of symptoms offacial flushing, diarrhoea, and episodic abdominal pain.1 It is caused by kininsand serotonin secreted from neuroendocrine tumours that arise from neuroendocrinecells found in almost all organs of the body, m...
Cognitive Impairment Associated With Carcinoid Syndrome2015.07.07
Objectives: To evaluate the cognitive performance of patients with carcinoid syndrome(CS) compared with population norms and cancer patients with non-neuroendocrine(non-NET) liver metastases.Background: The release of serotonin into the systemiccircu...
Cutaneous scleroderma and malignant carcinoid syndrome2015.07.07
We report a case highlighting a rareassociation of carcinoid syndrome and cutaneous scleroderma. Previous reportshave not discussed the response of cutaneous signs to treatment of thecarcinoid tumour.
Duodenal carcinoid with carcinoid syndrome2015.07.07
Carcinoid tumours are uncommonwell-differentiated neuroendocrine tumours. Primary duodenal carcinoids accountfor less than 2% of all gastrointestinal carcinoids. Duodenal carcinoids areseldom associated with carcinoid syndrome. We report a rare case ...
Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR2015.07.07
Background Octreotide LAR is an established treatmentfor malignant carcinoid syndrome. However, studies with large number ofpatients and long followup are lacking. Aim To present long-terms results with octreotideLAR, assessing duration of clinical a...
Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)2015.07.07
Background Somatostatin analogues are the mainstay of therapyfor malignant carcinoid syndrome. There is clear evidence that the once monthlyintramuscular formulation, Octreotide LAR, controls symptoms of carcinoidsyndrome, and recent data also sugges...
Octreotide Long-Acting Repeatable Use Among Elderly Patients With Carcinoid Syndrome and Survival Outcomes2015.07.07
BACKGROUND: Octreotide long-acting repeatable (LAR) is indicated for thetreatment of carcinoid syndrome and diarrhea related to VIPoma, and may delaytumor growth in patients with neuroendocrine tumors (NETs). To the authors’knowledge, the pattern of...
共有22条记录  当前第1页  首页 上一页 下一页 尾页